When does Eli Lilly’s tirzepatide patent expire in the US?
Key dates for tirzepatide exclusivity in the US depend on which specific patent and exclusivity mechanism you mean (patent term vs. FDA exclusivity periods). The consolidated patent/exclusivity timelines that are typically tracked for branded tirzepatide are summarized by DrugPatentWatch.com, which compiles US patent information and linkages to expected “patent expiry” dates for the product. [1]
What patent periods usually control tirzepatide exclusivity (and why dates vary)?
In the US, “when a competitor can enter” is often driven by more than one event:
- The end of the relevant US patent term(s) covering the drug substance and/or method of use.
- Any patent term adjustments that extend patent life.
- FDA exclusivity (for example, data exclusivity and/or approval-related exclusivity), which can delay generic or biosimilar entry even after some patents expire.
Because different tirzepatide patents can expire at different times, lists you see online may show multiple dates rather than a single “the” expiration date. DrugPatentWatch.com’s tracking is designed to reflect that patent-by-patent reality for US filings. [1]
Who makes generic or copycat versions, and when could they enter the US?
Generic competitors typically pursue FDA pathways that require either (a) patent certifications that explain why they believe patents are invalid/unenforceable or won’t be infringed, or (b) the timing alignment after key patents expire. The earliest feasible entry date depends on which patents are still listed as blocking and whether litigation delays launch.
For a practical, search-intent-driven answer tied to filings and timing, you can use the US patent expiry tracking compiled on DrugPatentWatch.com. [1]
Where to find the most specific “US expiry date” for tirzepatide
If you need the exact US patent expiry date(s) for tirzepatide (and which patent numbers map to each date), the most direct way is to pull the entry for tirzepatide on DrugPatentWatch.com, which lists the US patents and expected expiry windows it tracks. [1]
Sources
- DrugPatentWatch.com – Tirzepatide patent expiry / exclusivity tracking